The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2021 | CAR-NK: improved CRS and promising safety profiles in myeloma

Name: CAR-NK: improved CRS and promising safety profiles in myeloma
Uploaded: 2021-06-14T00:00:00Z
Duration: 1 min 6 s
Description: Leo Rasche, MD, University of Arkansas for Medical Sciences, Little Rock, AR, shares an update on chimeric antigen receptor natural killer cell (CAR-NK) therapy for multiple myeloma, highlighting reduced incidences of cytokine release syndrome (CRS) and promising tolerability profiles. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Leo Rasche • 14 Jun 2021

EHA 2021

Multiple Myeloma CAR-NK

Leo Rasche, MD, University of Arkansas for Medical Sciences, Little Rock, AR, shares an update on chimeric antigen receptor natural killer cell (CAR-NK) therapy for multiple myeloma, highlighting reduced incidences of cytokine release syndrome (CRS) and promising tolerability profiles. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.